Table 1 Clinicopathological characteristics of all enrolled patients (n = 25).
Variables | n | % | |
|---|---|---|---|
Sex | Male | 17 | 68.0 |
Female | 8 | 32.0 | |
Age (range) | 63 | 25–85 | |
ECOG performance status | 1 | 25 | 100 |
Pathological differentiation | W/D adenocarcinoma | 1 | 4.0 |
M/D adenocarcinoma | 17 | 68.0 | |
P/D adenocarcinoma | 2 | 8.0 | |
Mucinous adenocarcinoma | 4 | 16.0 | |
Signet ring cell carcinoma | 1 | 1.0 | |
Regimens including cetuximab | Irinotecan + cetuximab (+3rd line) | 11 | 44.0 |
FOLFIRI + cetuximab (1st line) | 10 | 40.0 | |
FOLFOX + cetuximab (1st line) | 4 | 16.0 | |
KRAS mutational status (direct sequencing) | Wild-type | 25 | 100 |
